TADG-14, Tumor Antigen Derived Gene, i.e. TADG, is a novel extracellular serine protease that has been identified and cloned from ovarian carcinoma. It is uniquely expressed in ovarian cancer, both in early stage and overt carcinomas. It is seldom or not at all expressed in normal adult tissues and has not been detected in other fetal tissues. This unique secreted protease offers the opportunity for use as a diagnostic in screening programs to detect ovarian cancer at early stage I and II. It also offers the potential as a target for therapeutic intervention through down-regulation of its protease activity or as a potential vaccine.

Reference: Cancer Research, 59, 4435 - 4439, September 1, 1999

97-19

Patent Status: U.S. Patents Issued #7,014,993; 7,067,250; 6,642,013; 7,083,790 and several National Filings

Licensing Status:  Available for exclusive licensing all fields, except diagnostics

Additional Licensing Partner(s) to commercialize all applications, Except Diagnostic